PD173074

Pfizer辉瑞授权 目录号:S1264

PD173074 Chemical Structure

Molecular Weight(MW): 523.67

PD173074是一种有效的FGFR1抑制剂,在无细胞试验中IC50约为25 nM,也能抑制VEGFR2,IC50为100-200 nM,作用于FGFR1比作用于PDGFR和c-Src选择性高1000倍左右。

规格 价格 库存 购买数量  
RMB 802.11 现货
RMB 575.36 现货
RMB 985.04 现货
RMB 3867.14 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的7个实验数据:

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331(6019), 912-6. PD173074 purchased from Selleck.

    Inhibition of FGFR signaling pathway by FGFR inhibitor PD173074 in mouse xenograft tumors. Bladder cancer SW780 cells were implanted in mice and treated with PD173074 after tumor formation as shown in B. Protein lysates of tumor tissues were prepared and immunoblotted with antibodies against phospho-ERK1/2, pan-ERK1/2, and γ-tubulin.

    Cancer Discov 2013 3(6), 636-47. PD173074 purchased from Selleck.

  • FGFR inhibitors block signaling in FGFR2-fusion-expressing cells. Activation of FGFR2 and MAPK by FGFR2-AHCYL1 and its suppression by FGFR inhibitors. Lysates from NIH3T3 cells expressing FGFR2-AHCYL1 or EZR-ROS1 (control) treated with vehicle (DMSO), 0.2 and 1 uM BGJ398, and 0.2 and 1 uM PD173074 were immunoblotted with the relevant antibodies. β-Actin was used as a loading control.

    Hepatology 2014 59(4) ,1427-34. PD173074 purchased from Selleck.

    The level of p-FRS2 was examined in the uterine sections of Msx1f/fMsx2f/f (upper panel) and Msx1d/dMsx2d/d (lower panel) mice on day 4 of pregnancy by immunohistochemistry. Magnification: a and d: 10 x, b and e: 20 x, c and f: 40x. FGFR-specific inhibitor PD173074 was applied to one uterine horn of Msx1d/dMsx2d/d (n = 3) mice on day 3 of pregnancy. The other horn served as vehicle-treated control. Uterine horns were collected on day 4 morning and sections were subjected to immunohistochemistry to detect p-FRS2, Ki67, and Muc-1.

    PLoS Genet 2012 8(2), e1002500. PD173074 purchased from Selleck.

  • Cells were incubated with DMSO control, 10 uM TGFBR inhibitor or 10 uM FGFR inhibitor PD173074 for 1 h. Cells were fixed, labeled with anti-GM130 (red) and analyzed by confocal microscopy. Images were analyzed using Image J (n = 3 experiments, >100 cells per condition). Scale bars, 10 uM.

    J Cell Sci 2014 10.1242/jcs.159608. PD173074 purchased from Selleck.

    Effects of antagonists for RAGE (FPS-ZM), TLR-4 (TAK-242) and FGFR1 (PD and BGJ) on the S100B-induced alterations in glucose metabolism in L6 cells treated for 6 h. (A) Effects of FPS-ZM, (B) TAK-242 and (C) PD and BGJ on the S100B inhibition of glucose consumption.

    Am J Physiol Endocrinol Metab, 2017, 312(6):E471-E481. PD173074 purchased from Selleck.

  • Effect of select kinase inhibitors on DF508-CFTR maturation analyzed by immunoblotting. 293MSR-GT cells stably expressing DF508-CFTR were treated with 15 uM kinase inhibitors or 0.3% DMSO (vehicle control), as indicated, grown at 37 ℃ for 48 h, and the appearance of the mature protein, band C, monitored by immunoblotting with anti-CFTR antibodies. Band B represents the immature protein. DMSO represents vehicle- alone control, 27℃ represents temperature rescue of F508-CFTR at 27℃, 37℃ represents untreated DF508-CFTR control, and WT represents WT-CFTR. Top panels depict the anti-CFTR immunoblot and bottom panels depict actin (loading) control. ** represents cellular toxicity.

    Biochem Bioph Res Co 2012 11(9), 745-57. PD173074 purchased from Selleck.

产品安全说明书

FGFR抑制剂选择性比较

生物活性

产品描述 PD173074是一种有效的FGFR1抑制剂,在无细胞试验中IC50约为25 nM,也能抑制VEGFR2,IC50为100-200 nM,作用于FGFR1比作用于PDGFR和c-Src选择性高1000倍左右。
靶点
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
~25 nM 100 nM-200 nM
体外研究

PD173074是FGFR1的ATP竞争性抑制剂, Ki约为40 nM。PD173074也是VEGFR2的有效抑制剂。相比FGFR1,PD173074弱抑制Src,INSR,EGFR,PDGFR,MEK和PKC的活性,IC 50值大1000倍以上。PD173074剂量依赖性地抑制FGFR1和VEGFR2的自身磷酸化,IC50 分别为1-5 nM和100-200 nM。[1] PD173074以剂量依赖的方式抑制FGF-2促进的颗粒神经元存活,IC50是12 nM,活性是SU 5402的1,000倍以上。[2] D173074特异性地抑制FGF-2-介导的少突胶质细胞(OL)谱系细胞的细胞增殖,分化和MAPK激活。[3] 在多发性骨髓瘤(MM)细胞系中,PD173074对野生受体和FGFR3突变有活性。PD173074还以剂量依赖的方式有效地抑制FGFR3的自磷酸化,IC50约为5 nM。PD173074有力地降低了表达FGFR3的KMS11细胞和KMS18细胞的活力,IC50小于20 nM。aFGF刺激的MM细胞生长受PD173074抑制是和FGFR3的表达高度相关的。PD173074完全抑制由Y373C FGFR3介导而不是的Ras介导的NIH 3T3转化,这表明PD173074专门针对FGFR3基因介导的细胞转化和缺乏非特异性的细胞毒性作用。PD173074也诱导KMS11和KMS18细胞功能成熟。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 NIf5TVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPrXXJKSzVyPUCuNFEzOjVizszN MmPKV2FPT0WU
KG-1 M3u2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\WTWM2OD1yLkC1NVI6KM7:TR?= NU\mXG9tW0GQR1XS
MFM-223 NUjhXnR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jRVWlEPTB;MD6yNVU4PiEQvF2= MUXTRW5ITVJ?
EoL-1-cell MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnYSXpKSzVyPUCuN|I6QDRizszN NYe1[49[W0GQR1XS
ECC10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOxTWM2OD1yLkOzPFk5KM7:TR?= MUHTRW5ITVJ?
H-EMC-SS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWGybHEyUUN3ME2wMlM1PzF3IN88US=> MXHTRW5ITVJ?
AN3-CA M4L5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoeyTWM2OD1yLkSwNVM{KM7:TR?= M3PG[3NCVkeHUh?=
HuO-3N1 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;K[FJvUUN3ME2wMlU1PjV|IN88US=> NIKwR5dUSU6JRWK=
RT-112 NEjxeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwNUS3NFEh|ryP NGTIe|lUSU6JRWK=
NEC8 NFvpZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjhcml5UUN3ME2wMlU3Ojh7IN88US=> NYOzNYRMW0GQR1XS
D-263MG NWfETHo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInBbFhKSzVyPUCuO|EyPTlizszN M4rKfHNCVkeHUh?=
SW962 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn70TWM2OD1yLke4PVg5KM7:TR?= Mm[zV2FPT0WU
BV-173 NFzUV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwOES2NlMh|ryP MnjSV2FPT0WU
MFE-280 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO5O2xKSzVyPUCuPFU5PzJizszN NV;TZVJ4W0GQR1XS
HuH-7 Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ftPGlEPTB;MT6yOFQ3PCEQvF2= MX;TRW5ITVJ?
RS4-11 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzpb45KSzVyPUGuN|M5QDZizszN MUnTRW5ITVJ?
DMS-114 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;SVYNQUUN3ME2xMlM3PzN5IN88US=> MknFV2FPT0WU
MSTO-211H MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXQTWM2OD1zLkS3N|c5KM7:TR?= M{\1dnNCVkeHUh?=
DU-145 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nwNWlEPTB;MT61PFIyPyEQvF2= MUTTRW5ITVJ?
A172 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK4TWM2OD1zLkewN|U2KM7:TR?= MWLTRW5ITVJ?
SBC-1 MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn2U4tPUUN3ME2yMlA6PCEQvF2= NGPSem1USU6JRWK=
H9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi0TohHUUN3ME2yMlE1OzB4IN88US=> NULnW2g5W0GQR1XS
NCI-SNU-1 NGXpV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrhTWM2OD1{LkG4N|k1KM7:TR?= NVrp[lFCW0GQR1XS
NCI-H720 NETZcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT2TWM2OD1{LkKxNlg{KM7:TR?= M1HsdnNCVkeHUh?=
HCC2218 NFToW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLtTWM2OD1{LkO3PVM6KM7:TR?= M3z1ZnNCVkeHUh?=
G-401 NV3WW41mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HRZ2lEPTB;Mj60O|E5QSEQvF2= M4XpSXNCVkeHUh?=
MPP-89 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHXeGlVUUN3ME2yMlQ5OzZ2IN88US=> MlXuV2FPT0WU
697 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj2TYN1UUN3ME2yMlY2OzNzIN88US=> NGTpVlZUSU6JRWK=
KARPAS-45 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvB[mF6UUN3ME2yMlcxPzR5IN88US=> NXvPVXRWW0GQR1XS
MG-63 NGLYdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwOUSyOlIh|ryP MV;TRW5ITVJ?
NTERA-S-cl-D1 NHLOW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTNwMEO0O|Ih|ryP NYrLWoR6W0GQR1XS
G-402 NU[1ZlAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnJ[ZBRUUN3ME2zMlEzPzJ5IN88US=> M3zHdHNCVkeHUh?=
NKM-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjRTWM2OD1|LkGzOVY1KM7:TR?= M4S3U3NCVkeHUh?=
RH-18 NULTeFZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zDSWlEPTB;Mz6xPVU6QCEQvF2= NGXXTVJUSU6JRWK=
NCI-H1092 M4X5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfnO2ZKSzVyPUOuNVk3QSEQvF2= M135UnNCVkeHUh?=
RPMI-8226 M1Pzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPvUYdKSzVyPUOuNlM1PDdizszN MlrlV2FPT0WU
GAMG MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m5XGlEPTB;Mz60OlU4PiEQvF2= NWHCfo8{W0GQR1XS
HH MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXnO|lMUUN3ME2zMlQ4Pjd4IN88US=> M3jrdnNCVkeHUh?=
RO82-W-1 NWK2UY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vx[GlEPTB;Mz60PVg2PSEQvF2= MVfTRW5ITVJ?
CCRF-CEM MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HSPWlEPTB;Mz61NFQ5QCEQvF2= NIfTb2JUSU6JRWK=
NBsusSR NEDXTZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTEU|g1UUN3ME2zMlY{QTZ7IN88US=> MoW0V2FPT0WU
CHL-1 NI\5foNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm3TWM2OD1|Lk[1O|k6KM7:TR?= MYfTRW5ITVJ?
LK-2 NV65TWhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwNkexN|Mh|ryP MYjTRW5ITVJ?
Hs-578-T NHLqNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfaRYlKSzVyPUOuOlc5PzNizszN NXTnfIxSW0GQR1XS
CTB-1 NXjuOlZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnnTWM2OD1|LkiwNFUyKM7:TR?= NXfZU2NUW0GQR1XS
ES5 NHP1[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjDcYpKSzVyPUOuPFM3OzdizszN MoOyV2FPT0WU
A204 MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNwOUKwO|Uh|ryP M2CzfXNCVkeHUh?=
SW780 MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwOUKyOFUh|ryP MWHTRW5ITVJ?
EW-3 M37qcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L4fGlEPTB;Mz65PFkzOyEQvF2= MnLGV2FPT0WU
A704 M{DoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\VVlRKSzVyPUSuNlg4OjNizszN MXvTRW5ITVJ?
LU-139 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjRNYRKSzVyPUSuN|E2OzRizszN NX3xeHZ4W0GQR1XS
CAL-72 NHzqe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRwNEG3OFYh|ryP NY[3bmhTW0GQR1XS
D-336MG Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[yXWlEPTB;ND60OlgyPyEQvF2= M{PITnNCVkeHUh?=
LAMA-84 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojxTWM2OD12LkWzN|Eh|ryP NFn3WXRUSU6JRWK=
GI-ME-N NH7DTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPOTWM2OD12LkW0PFEh|ryP NFX4[XBUSU6JRWK=
KM-H2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy5NFFKSzVyPUSuOVUzOjJizszN NIqyO2pUSU6JRWK=
NCI-H209 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTLTWM2OD12LkW4Nlg{KM7:TR?= NHjGXHdUSU6JRWK=
IGROV-1 NFznfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe0V3N5UUN3ME20Mlg4OTZ6IN88US=> NFmxOJVUSU6JRWK=
L-363 NYrXV3d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTRwOU[2OlUh|ryP NUi1O2JkW0GQR1XS
SK-MEL-3 NY\YbJFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSyTWM2OD13LkK0NFYh|ryP M3qzU3NCVkeHUh?=
HuO9 M17HXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G0XWlEPTB;NT6zPFg1OyEQvF2= MlvEV2FPT0WU
NOS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDjTYxKSzVyPUWuO|I6OjdizszN NUDuVGpoW0GQR1XS
NCI-H1770 M1fWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTVwOUWwN|Ih|ryP NUjSNYpXW0GQR1XS
SF126 NEDjSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZwMkG0NFYh|ryP MYHTRW5ITVJ?
ML-2 NV;JWHRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTZwMkS5O|ch|ryP NVG4[WFGW0GQR1XS
CHP-134 NWrofW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nVcWlEPTB;Nj6yOVE5OiEQvF2= NHnNNY9USU6JRWK=
NCI-H1355 NYroTFNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvhTWM2OD14LkSxO|M{KM7:TR?= Mm\JV2FPT0WU
TE-12 M4DHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\DWmlEPTB;Nj63NlY4OSEQvF2= MmDDV2FPT0WU
A4-Fuk NH\ifYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTZwN{OxOFIh|ryP M1rkbHNCVkeHUh?=
MV-4-11 M1fvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq0TWM2OD14Lke2OlI3KM7:TR?= NEPwNFdUSU6JRWK=
SK-UT-1 NWjTOJZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTWeZVKSzVyPU[uPVE4QDRizszN MoT6V2FPT0WU
J-RT3-T3-5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrHVZJNUUN3ME23MlA4PzZ2IN88US=> NIPofmVUSU6JRWK=
ME-180 NV7iNoV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTdwMUC0NFQh|ryP NHHWSXZUSU6JRWK=
SK-MEL-28 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLoTWM2OD15LkO3PFE6KM7:TR?= MUPTRW5ITVJ?
HAL-01 NYPWVZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjZNIl{UUN3ME23MlQ5OzRzIN88US=> M1zi[3NCVkeHUh?=
ES8 MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjHU|VpUUN3ME23MlY6PjJ4IN88US=> MVfTRW5ITVJ?
DB MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED5PFFKSzVyPUiuNVE2ODRizszN NFLPfYVUSU6JRWK=
SK-NEP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPtTWM2OD16LkS4NVQ6KM7:TR?= MWXTRW5ITVJ?
COR-L88 NX3KXnZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDFTWM2OD16LkWwPVgyKM7:TR?= NFnCbJpUSU6JRWK=
LB1047-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\v[mVKSzVyPUiuOVIzOTJizszN NHrMVolUSU6JRWK=
NCI-H520 M2r5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjmWZNOUUN3ME24MlYzOTV5IN88US=> Mn\RV2FPT0WU
SW954 NUf3[JVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S4cWlEPTB;OD62PVc5PiEQvF2= MXPTRW5ITVJ?
TE-6 NWfVPVFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TuU2lEPTB;OD63OVE1OyEQvF2= NGKw[G1USU6JRWK=
D-283MED M2Lqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj4NZRFUUN3ME25MlA3PTN2IN88US=> MWDTRW5ITVJ?
DBTRG-05MG MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe1dXpVUUN3ME25MlA6PjB5IN88US=> NYfMcYRXW0GQR1XS
NCI-H446 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7jT49NUUN3ME25MlI6PTJ4IN88US=> NULlUJptW0GQR1XS
HOS NY\aNoNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\H[lhKSzVyPUmuN|UyOzRizszN MnjYV2FPT0WU
ES4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq2TWM2OD17LkWwOVk2KM7:TR?= NG\EWmNUSU6JRWK=
EW-13 M4rqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfJTWM2OD17Lki5NFU2KM7:TR?= MWHTRW5ITVJ?
IST-MES1 NYX6cFN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTlwOUS1N|Qh|ryP M4W4eXNCVkeHUh?=
CAS-1 NFPkSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TJcmlEPTB;OT65O|Y2QSEQvF2= M3r4fXNCVkeHUh?=
EM-2 NXrqVoNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nEWmlEPTB;MUCuNVM6OyEQvF2= NEDCWFFUSU6JRWK=
SW948 NWC3V3RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFyLkG4PFIh|ryP M3HXeHNCVkeHUh?=
OAW-42 M1T3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzaTWM2OD1zMD61NlY4KM7:TR?= M{XBeHNCVkeHUh?=
BE-13 M17HV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP4UlJmUUN3ME2xNE43PTd4IN88US=> NYTZU|RWW0GQR1XS
KU812 MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml65TWM2OD1zMD63N|kyKM7:TR?= MYXTRW5ITVJ?
SK-MEL-30 M1WzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i5fmlEPTB;MUCuPFkxOSEQvF2= NF\JU5dUSU6JRWK=
A2780 NF31VFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTpVXBJUUN3ME2xNU4xOzB6IN88US=> M{X6W3NCVkeHUh?=
TGBC24TKB MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFzLkC3N|ch|ryP M{\0NnNCVkeHUh?=
GOTO M1vZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF36cpNKSzVyPUGxMlIxQDRizszN M2C1WXNCVkeHUh?=
NCI-H526 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFzLkO4N|ch|ryP NVLZXVRzW0GQR1XS
BHT-101 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvvUm5KSzVyPUGxMlQ1PTZizszN MnS0V2FPT0WU
NCI-H1155 M1;ZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrOZ5lPUUN3ME2xNU41QTR5IN88US=> M4nGNnNCVkeHUh?=
MCF7 MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG0TWM2OD1zMT62NVY4KM7:TR?= MXTTRW5ITVJ?
MKN45 NV3YUWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDITWM2OD1zMT63PVk{KM7:TR?= M1XYRXNCVkeHUh?=
MOLT-16 Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTBfI5EUUN3ME2xNU46Pjl{IN88US=> M{jtXXNCVkeHUh?=
YH-13 NWf2VZFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrZTWM2OD1zMj6wN|Q3KM7:TR?= NFnuW5ZUSU6JRWK=
P12-ICHIKAWA M3W2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF{LkO4OFUh|ryP MWTTRW5ITVJ?
GR-ST M4LCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fVTGlEPTB;MUKuOVI6PSEQvF2= NWLvfY1KW0GQR1XS
CAKI-1 M{Xke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u2dGlEPTB;MUKuO|kyKM7:TR?= NVX4TVNQW0GQR1XS
LXF-289 NFy5TYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[xTWM2OD1zMz6wPFM2KM7:TR?= NXPxcZQ{W0GQR1XS
MHH-PREB-1 M3rXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHDbXZKSzVyPUGzMlI4ODRizszN NH\ZWmNUSU6JRWK=
EW-16 NELaT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e3OWlEPTB;MUOuN|E5PyEQvF2= MoPmV2FPT0WU
NCI-H82 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TEPGlEPTB;MUOuOFE6PSEQvF2= MkjXV2FPT0WU
MMAC-SF MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Ts[WlEPTB;MUOuOFU1PyEQvF2= MnL3V2FPT0WU
COLO-684 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF|LkWzNVgh|ryP MnLIV2FPT0WU
QIMR-WIL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCyTWM2OD1zMz64NVA6KM7:TR?= MYHTRW5ITVJ?
NB69 NFHxWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fiOmlEPTB;MUOuPVg3QCEQvF2= NXrYR3RsW0GQR1XS
NCI-H2291 M1rTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nrVWlEPTB;MUSuOFQ2OyEQvF2= NIjiXXlUSU6JRWK=
MKN7 MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LaUmlEPTB;MUSuOlY4PiEQvF2= MX;TRW5ITVJ?
HDLM-2 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrFUXdKSzVyPUG1MlEzQDZizszN NGDmWoJUSU6JRWK=
A253 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rGWmlEPTB;MUWuN|g3QSEQvF2= MWXTRW5ITVJ?
SK-LU-1 NWH3SndiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXPbo9KSzVyPUG1MlkxQTRizszN MlPyV2FPT0WU
MEG-01 NUjHbWpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOyTWM2OD1zNT65NVA4KM7:TR?= MVPTRW5ITVJ?
SK-N-DZ MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF3LkmzO|Yh|ryP MlTJV2FPT0WU
H4 M3;IS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO5TWM2OD1zNj6wPFgh|ryP MmL5V2FPT0WU
LU-65 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\2U4JKSzVyPUG2MlM{QDRizszN M{HlcXNCVkeHUh?=
NCI-H1048 M3TlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfRbYNKSzVyPUG2MlUyPjVizszN NUfqTm5EW0GQR1XS
LCLC-97TM1 NUnrTmZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W0XWlEPTB;MU[uOVg5QSEQvF2= MnHNV2FPT0WU
CAL-120 M1zKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF4Lkm4O|kh|ryP M2XhXHNCVkeHUh?=
LU-134-A NHHoS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrGOJkxUUN3ME2xO{4{OzlzIN88US=> NX76bnd7W0GQR1XS
SK-MEL-1 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF5LkexNlch|ryP M1ztNHNCVkeHUh?=
NCI-H69 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInQZldKSzVyPUG3Mlk{ODdizszN MojmV2FPT0WU
MC116 NFjTPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTL[INKSzVyPUG3Mlk4PSEQvF2= NHHKSZZUSU6JRWK=
UMC-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXXTWM2OD1zOD6xO|g5KM7:TR?= MmrMV2FPT0WU
HCC1395 NVXQfYNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF6LkSzNFEh|ryP MV7TRW5ITVJ?
no-10 M1PIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm4fI9wUUN3ME2xPE43Ozh6IN88US=> M2LUO3NCVkeHUh?=
NY MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rUbWlEPTB;MUmuNFgxQSEQvF2= M1f6NXNCVkeHUh?=
OS-RC-2 NEPjV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULWW5RzUUN3ME2xPU4yOjV{IN88US=> MYLTRW5ITVJ?
D-423MG NFXrZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\qd2lEPTB;MUmuN|k2OiEQvF2= NYrQXGh2W0GQR1XS
LC-2-ad M12yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\EZpZyUUN3ME2xPU44PjF{IN88US=> NYjafY5GW0GQR1XS
DU-4475 NETCT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGwdZJoUUN3ME2xPU45QDV{IN88US=> MmPLV2FPT0WU
YKG-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTZTWM2OD1zOT65OlIh|ryP MojEV2FPT0WU
HCC1569 M3XX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;tVGlEPTB;MkCuNlYzPCEQvF2= NWj5XY92W0GQR1XS
TYK-nu NWTlS4NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HicWlEPTB;MkCuNlg1PyEQvF2= MVPTRW5ITVJ?
DEL M4XRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJyLkm4NFgh|ryP M4jIPXNCVkeHUh?=
MHH-ES-1 NWHDcXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH5TWM2OD1{MT6zOVk4KM7:TR?= MX7TRW5ITVJ?
KARPAS-299 M3X5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fUeGlEPTB;MkGuOVI6KM7:TR?= NHrjTIRUSU6JRWK=
CTV-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LmUWlEPTB;MkGuOlE4OiEQvF2= NVLyN4NDW0GQR1XS
NCI-H2452 MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;1bpNpUUN3ME2yNk43Pjd5IN88US=> NEHWNGhUSU6JRWK=
D-566MG NHPXW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ{Lke2NFEh|ryP MoPsV2FPT0WU
EFO-27 M1jsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnmT3RmUUN3ME2yN{4xPjVzIN88US=> MmLuV2FPT0WU
NCI-H596 NH7YNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTWVoZrUUN3ME2yN{45PTJ5IN88US=> NX;HSpdHW0GQR1XS
KS-1 NYHnbHgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[0TWM2OD1{ND6yO|U6KM7:TR?= NV7ud4s3W0GQR1XS
8305C MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPuc5NrUUN3ME2yOE41ODR3IN88US=> NUX1dHJQW0GQR1XS
A427 NVP0PIF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDFcHBKSzVyPUK1MlA{OjNizszN NV6zTY9yW0GQR1XS
COLO-800 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ3LkGwOlEh|ryP MXHTRW5ITVJ?
SJRH30 NHPKRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjqW29KSzVyPUK1MlM6ODhizszN NX3FSW4yW0GQR1XS
MEL-HO NFKxXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnEVlA1UUN3ME2yOU41OzF7IN88US=> MYrTRW5ITVJ?
FTC-133 NFTvZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O3fGlEPTB;MkWuPFE5PiEQvF2= MY\TRW5ITVJ?
SF295 M3vuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnCV3VQUUN3ME2yOk4zQTZizszN MmrqV2FPT0WU
SW1710 M4DDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV65SolZUUN3ME2yOk41OTJ|IN88US=> NXjNV|JpW0GQR1XS
EFM-19 NH3nUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC2cJNKSzVyPUK2MlgyPDVizszN NV7zbo43W0GQR1XS
NB10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LHe2lEPTB;MkiuNlI6PyEQvF2= NUDW[5N3W0GQR1XS
TK10 NFGzW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlznTWM2OD1{OD6yN|k6KM7:TR?= M{PPSHNCVkeHUh?=
D-502MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr5[WhTUUN3ME2yPE41KM7:TR?= M1:3eHNCVkeHUh?=
EW-18 NFfqXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe3TWM2OD1{OD60N|g3KM7:TR?= NHXDXVVUSU6JRWK=
VMRC-RCZ M2jaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe3TWM2OD1{OD65OFEh|ryP MXvTRW5ITVJ?
Ca9-22 M1;1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ7LkS1OVch|ryP NEnyPXpUSU6JRWK=
KYSE-70 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjkTWM2OD1{OT61O|g3KM7:TR?= MYfTRW5ITVJ?
A101D MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXBOnltUUN3ME2yPU43PDd{IN88US=> NYXqfGZLW0GQR1XS
WM-115 M4\XNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWWzOI44UUN3ME2yPU44PjB5IN88US=> NVTmbWRYW0GQR1XS
HCC2157 NUXuXIsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;5TWM2OD1{OT64PFA4KM7:TR?= MmPuV2FPT0WU
TE-9 NYHXbVNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TkWWlEPTB;MkmuPFg3PSEQvF2= NEjMXGtUSU6JRWK=
K-562 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNyLkC5N|Mh|ryP MWPTRW5ITVJ?
SN12C NWrCbI9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNyLkG0NlYh|ryP MUfTRW5ITVJ?
ESS-1 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITKfnlKSzVyPUOwMlQ4PTlizszN MoLBV2FPT0WU
K5 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXUR4pJUUN3ME2zNE44PjRizszN NFfPVVNUSU6JRWK=
J82 NIrpUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnVOWNKSzVyPUOxMlA5QTdizszN MnrkV2FPT0WU
HOP-92 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHRXnF{UUN3ME2zNU4yOTFzIN88US=> NE\PVVRUSU6JRWK=
NCI-H2228 NGT2VnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\CTWM2OD1|MT6zNlk3KM7:TR?= NEHyUpNUSU6JRWK=
OCI-AML2 NHfzNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\zTIZvUUN3ME2zNU4{PjFizszN MWfTRW5ITVJ?
NCI-SNU-5 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTNzLkixN|ch|ryP NXXHRVBLW0GQR1XS
A3-KAW MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTjTWM2OD1|MT65NlQ{KM7:TR?= NFzObHNUSU6JRWK=
LCLC-103H MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP6TWM2OD1|Mj6wNVcyKM7:TR?= NX\p[ZRvW0GQR1XS
KY821 M1v1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknyTWM2OD1|Mj62PFg1KM7:TR?= MY\TRW5ITVJ?
JVM-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnUOG1NUUN3ME2zNk46ODd7IN88US=> MV7TRW5ITVJ?
Mo-T M3nK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TWXmlEPTB;M{OuNVAxPSEQvF2= MYnTRW5ITVJ?
IA-LM MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTN|LkK3OUDPxE1? MmTuV2FPT0WU
C8166 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN|LkOxPVIh|ryP M{T1XHNCVkeHUh?=
TCCSUP MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTN|LkSzNFch|ryP MUTTRW5ITVJ?
JEG-3 NYqwO4E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN|LkS3Olgh|ryP MmPaV2FPT0WU
MS-1 NGnVSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTN|LkW1OVEh|ryP NF25T|lUSU6JRWK=
NCI-H1304 NFTvWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjCSXlKSzVyPUOzMlU4OjVizszN MWrTRW5ITVJ?
Ramos-2G6-4C10 NH3rSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPJTXJ{UUN3ME2zOE4xOzN3IN88US=> NFzKSmJUSU6JRWK=
MDA-MB-453 NHX3UGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLmWJFQUUN3ME2zOE43Ozl3IN88US=> MWDTRW5ITVJ?
KYSE-520 Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGwVnFKSzVyPUO0MlcyQDFizszN MnPqV2FPT0WU
SW900 M3zBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y0[GlEPTB;M{SuPFEyPSEQvF2= NF3QW49USU6JRWK=
HCC2998 NGPVcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELJOnBKSzVyPUO1MlE2OjlizszN M3HoUHNCVkeHUh?=
A2058 M1nZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLITWM2OD1|NT62NFYyKM7:TR?= MmDCV2FPT0WU
OVCAR-3 NETFOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ny[2lEPTB;M{[uNlA1PSEQvF2= MVvTRW5ITVJ?
MOLT-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[1fnpuUUN3ME2zOk4zOjl2IN88US=> MlzOV2FPT0WU
CAPAN-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDZd5hPUUN3ME2zOk41Pjl7IN88US=> MVrTRW5ITVJ?
SCC-9 NHLQfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfzTWM2OD1|Nz60NFI4KM7:TR?= NYXmfpZTW0GQR1XS
SF268 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTpZYtKSzVyPUO4MlM1OzNizszN MlTOV2FPT0WU
HGC-27 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jNTWlEPTB;M{iuN|cyOSEQvF2= NGC5NW9USU6JRWK=
DOHH-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqzTG96UUN3ME2zPE44OTV6IN88US=> MnzNV2FPT0WU
KE-37 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT1TWM2OD1|OD65PFI5KM7:TR?= NWPSO3Q4W0GQR1XS
MOLT-13 M4Llc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[yTWM2OD1|OT6yOVAzKM7:TR?= M173VHNCVkeHUh?=
ES1 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT0WXlKSzVyPUO5MlM5PSEQvF2= MlrTV2FPT0WU
SK-OV-3 NITudXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j0TGlEPTB;M{muPVY1OyEQvF2= MXvTRW5ITVJ?
SNU-449 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjuPWlKSzVyPUSwMlA4PjRizszN NFjP[FlUSU6JRWK=
KYSE-510 NH3Bb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ZTWM2OD12MD6xNlk2KM7:TR?= NXrGO2JKW0GQR1XS
HL-60 NV73V5JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KwSGlEPTB;NECuPVc5OyEQvF2= NX7Ub4FsW0GQR1XS
DJM-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jaZ2lEPTB;NECuPVc6QSEQvF2= MYrTRW5ITVJ?
TGBC11TKB NIPLNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3OXnBKSzVyPUSxMlA6OjZizszN MV;TRW5ITVJ?
U-2-OS M1LlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrHTWM2OD12Mj6yOlQyKM7:TR?= NYD6R5ptW0GQR1XS
NCI-H2030 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTWTWM2OD12Mj60N|Y5KM7:TR?= NXm4TItKW0GQR1XS
LU-135 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD2TWM2OD12Mj61OFQ4KM7:TR?= MVXTRW5ITVJ?
ZR-75-30 M{O3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LVcWlEPTB;NEOuNFQ6OyEQvF2= NXqySI5EW0GQR1XS
GT3TKB MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHKTWM2OD12Mz6yOlc6KM7:TR?= MWjTRW5ITVJ?
RPMI-2650 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomxTWM2OD12Mz63PFE3KM7:TR?= NYrrfZFMW0GQR1XS
SAS M1nHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrYdGhKSzVyPUSzMlk2OzRizszN NEfjUI1USU6JRWK=
MDA-MB-231 NF;ZS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPSTWM2OD12Mz65OlA6KM7:TR?= NUDieVJ6W0GQR1XS
JVM-3 NWexSXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq0TWM2OD12ND6wOVM{KM7:TR?= NFPEN3JUSU6JRWK=
COLO-320-HSR NVjjfINPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfRTWM2OD12ND61OlM{KM7:TR?= M1q2U3NCVkeHUh?=
SNB75 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjXTWM2OD12ND62NVA2KM7:TR?= M2fvOnNCVkeHUh?=
NCI-H441 M{mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKxUFBKSzVyPUS0Mlk{OjhizszN NVHSOZZEW0GQR1XS
HCT-116 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jHZmlEPTB;NESuPVg3QCEQvF2= NIXMfYVUSU6JRWK=
NCI-H226 M3n5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTR3Lk[zOlgh|ryP MYfTRW5ITVJ?
CAL-33 NF30SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonrTWM2OD12NT65NlE4KM7:TR?= NUjoblRjW0GQR1XS
NCI-H1437 NGPEeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PqVmlEPTB;NE[uN|IyKM7:TR?= NHn0RpNUSU6JRWK=
HCC1187 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17JRWlEPTB;NE[uOFI2PSEQvF2= M1\w[HNCVkeHUh?=
NUGC-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzKTWM2OD12Nj61O|A6KM7:TR?= NXfsNnJZW0GQR1XS
T98G MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXLcXhzUUN3ME20O{42PDdizszN NGDqZ2JUSU6JRWK=
OVCAR-8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXaTWM2OD12Nz62PFMh|ryP NEn0eXFUSU6JRWK=
LB2241-RCC M4GzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrUR4tKUUN3ME20O{44OjdizszN NVrxOXc1W0GQR1XS
NCI-H358 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLLS2FXUUN3ME20PE4yOTV{IN88US=> NIDG[oxUSU6JRWK=
PANC-08-13 M17nWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHjRZRKSzVyPUS4MlE5PTNizszN NVSzcVhqW0GQR1XS
KP-N-YN M{\wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPFNXBKSzVyPUS4MlIyODJizszN MYDTRW5ITVJ?
NCI-H1755 M4TWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH3[mF7UUN3ME20PE4zPzJ4IN88US=> NVTseW9FW0GQR1XS
NCI-N87 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO2TWM2OD12OD6yPVkyKM7:TR?= M4rVNXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 PD173074在1 mg/kg/day或2 mg/ka/day对小鼠给药可以剂量依赖性的方式有效阻止由FGF或VEGF诱导的血管生成,并没有明显的毒性。[1] PD173074抑制FGFR3突变体转染的NIH 3T3细胞在裸鼠体内生长。在KMS11异种移植瘤模型中,PD173074抑制FGFR3导致肿瘤生长延缓,小鼠的存活率提高。[4] 在H-510异种移植体中,PD173074阻断肿瘤生长和cisplatin相似,与对照假治疗的动物相比增加中位生存期。在H-69异种移植体中,PD173074在50%小鼠中的诱导作用长于6个月。这些效应是和切除肿瘤中增加的细胞凋亡相关的,而非破坏肿瘤血管。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

体外激酶抑制试验:

检测是使用全长FGFR-1激酶在100微升含25 mM HEPES缓冲液(pH7.4),150 mM氯化钠,10 mM MnCl2,0.2 mM的原钒酸钠,750 μg/mL谷氨酸和酪氨酸(4:1)的无规共聚物,各种浓度的PD173074,和60至75 ng酶中进行的。该反应通过加入[γ-32P]ATP(含有0.4 μCi of [γ-32P]ATP的5 μM ATP)起始,样品在25°C孵育10分钟。反应通过加入30%三氯乙酸和材料的沉淀到玻璃纤维滤垫上终止。过滤器用15%三氯乙酸洗涤三次,掺入[32P]到谷氨酸酪氨酸聚合物衬底是通过计算保留在过滤器上的放射性来确定,通过WALLAC1250 betaplate阅读器读取。非特异性的活性被定义为温育不含酶的样品保留在过滤器上放射性。特异活性被确定为总活性(酶加缓冲液)减去非特异性活性。PD173074抑制FGFR-1的酶活性的IC50浓度用图解法测定。
细胞实验:[4]
+ 展开
  • Cell lines: KMS11和 KMS18
  • Concentrations: 溶解在DMSO中至终浓度~100 nM
  • Incubation Time: 48小时
  • Method: 在aFGF/肝素的存在下,细胞在PD173074浓度梯度中孵育48小时。活细胞的百分比由MTT法检测。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 诱导角膜新生血管的瑞士韦伯斯特小鼠
  • Formulation: 无菌准备
  • Dosages: 约2 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+corn oil
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 523.67
化学式

C28H41N7O3

CAS号 219580-11-7
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the half-life of PD173074(S1264) in vivo?

  • 回答:

    According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

相关FGFR产品

Tags: 购买PD173074 | PD173074供应商 | 采购PD173074 | PD173074价格 | PD173074生产 | 订购PD173074 | PD173074代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID